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ABSTRACT
The platinum (II) complexes, cis-[PtCI2(CH3SCH2CH2SCH3)] (Ptl), cis-[PtCl2(dmso)2] (dmso is
dimethylsulfoxide; Pt2) and cis-[PtCl2(NH3)2] (cisplatin), and taxol (T) have been tested at different
equimolar concentrations. Cells were exposed to complexes for 2 h and left to recover in fresh medium for
24, 48 or 72 h. Growth inhibition was measured by tetrazolium WST1 assay. Analyses of the cell cycle and
apoptosis were performed by flow cytometry, at the same exposure times. The IC50 value of each
platinum(II) complex as well as combination index (CI; platinum(iI) complex + taxol) for various
cytotoxicity levels were determined by median effects analysis.
MCF7 cells were found to be sensitive to both Ptl and Pt2 complexes. These cisplatin analogues
influenced the cell growth more effectively as compared to cisplatin. Cytotoxic effect was concentration and
time-dependent. Profound growth inhibitory effect was observed for Ptl complex, across all its
concentrations at all recovery periods. A plateau effect was achieved three days after treatment at Ptl
concentrations < laM. Pt2, however, decreased MCF7 cells survival only for the first 24 h ranging between
50-55%. Pt2 cytotoxicity sharply decreased thereafter, approaching 2 h treatment cytotoxicity level. The
median ICS0 values for Ptl and Pt2 were similar (0.337 and 0.3051 tM, respectively) but only for the first 24
h. The IC50 values for Ptl strongly depend on the recovery period. On simultaneous exposure of cells to
taxoland platinum(II) complexes no consistent effect was found. The Cls for combinations of taxol with Ptl
or Pt2 revealed cytotoxic effects that were in most cases synergistic (Ptl) or less than additive (Pt2). Flow
cytometry analysis has shown that each platinum(II) complex induced apoptosis in MCF7 cells. The level of
apoptosis correlated with cytotoxicity level for the range concentrations. Both cisplatin analogues, at IC50
concentrations, increased the number of MCF7 cells in GOGI phase of cell cycle. Pt2-treated cells remained
arrested in G0G phase up to 72 h after treatment. Combination of Pt2 and taxol caused further arrest of cells
in GOG1 phase (24 h) in parallel with strong decrement ofG2M phase cells.
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This study showed that two cisplatin analogues, Ptl and Pt2, with sulfur-containing carrier ligands,
influence the MCF7 cells growth more effectively as compared to the parent drug. They differ in their
eytotoxieity profiles and in their interaction with taxol as well. The cell cycle changes and induction of
apoptosis in MCF7 cells implicate a programmed cell death pathway in cell-killing.
Key words: Platinum complexes; Cell growth; Apoptosis; Cell cycle; Breast cancer cell line.
INTRODUCTION
Cisplatin, cis-[PtCl2(NHs)2], is a widely used antieaneer drug. The drug’s greatest therapeutical impact
was found to be on testieular and ovarian cancers/1/. It has also proved to be of benefit in the treatment of
wide variety of other solid tumors (head and neck, lung, bladder, eoloreetal and breast cancer) in combination
chemotherapy regimens. Because of its severe toxicity profile and the spontaneous development of drug
resistance in tumors, numerous Pt(II) and Pt(IV) complexes have been synthesized and tested for antitumor
activity/3/. The principal goal of these investigations is obtaining an antitumor drug with higher solubility,
better antitumor activity, and lower toxicity. However, at present, only several platinum(II) complexes
(earboplatin and oxaliplatin) have shown substantial antieaneer activity in clinical settings. Despite this
progress, the search for other platinum chemotherapeutic agents is continuing, since the carboplatin and other
second-generation platinum(ll) complexes, although less toxic than cisplatin, appear to be highly cross-
resistant with cisplatin.
The great majority of the second-generation antitumor active platinum complexes are structural analogues
of cisplatin with two ammine or amine groups in cis-position. The presence of the N-H groups on the
platinum antitumor active complex is likely required for a hydrogen bond donor function, although steric
effects cannot be excluded a priori/3/. But, most important is that new compounds should lack cross-
resistance to cisplatin and carboplatin/4/, it is already known that this requirement can be reached by using
non-ammonia ligands.
Cisplatin and taxol are highly suited for combination chemotherapy since they have distinct mechanisms
of action/5/. Taxol is used in combination with cisplatin in treatment of metastatic breast cancer patients who
have experienced resistance or refractory effects to anthracyclines /1,6/. Taxol, unlike other common
antimicrotubule agents, promotes microtubule assembly (enhances the polymerization of tubule) and thus
disrupts the dynamic equilibrium within the microtubule system. Due to that, cells are blocked in the late
G2/M phase of cell cycle followed by inhibition of cell proliferation.
The aim of the study was to examine the effects of two cisplatin analogues with sulfur-containing carrier
ligands on the growth, induction of apoptosis and cell-cycle parameters of MCF7 human breast cancer cell
line. The platinum(ll) complexes, cis-[PtCI2(CHaSCHCH2SCH3)] (Ptl) and cis-[PtCl(dmso)z]) (Pt2), were
analyzed as single agents or simultaneously with taxol at equimolar concentrations.
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EXPERIMENTAL
Chemicals and Materials
Distilled water was demineralized and purified to a resistance greater than 10 Mr) cm. The compounds
K2[PtCI4], dimethylsulfoxide (dmso) were obtained from Aldrich Chemical Co. and used without further
purification. The ligand CH3SCH2CH2SCH3 was prepared by adding two equivalents of CH3I to the
corresponding sodium salt of dithiol ligand in water solution/7/.
All common chemicals were of reagent grade.
Cell line
MCF7, human breast adenocarcinoma, estrogen receptor positive (ER+) cells grow as monolayer in
Dulbecco’s modified Eagle’s medium (DMEM). with 4.5% of glucose, supplemented with 10% of fetal calf
serum (FCS, NIVNS) and antibiotics: 100 IU/ml of penicillin and 100 lag/mg of streptomycin (ICN
Galenika). Cells were cultivated in flasks (Costar, 25cm2) at 310 K in the atmosphere of 100% humidity and
5% of COz (Heraeus). Exponentially growing viable cells were used through the assays. The viable cells
were determined by dye exclusion test (DET) with trypan blue/8/.
Platinum Complexes
The complexes cis-[PtC12(CHsSCH2CH2SCH3)] and cis-[PtCl2(dmso)2] were prepared from K2PtCI4
according to literature procedures /9,10/. The purity of these complexes was checked by elemental
microanalyses and 1H NMR measurements. The complexes were tested alone or simultaneously with taxol at
equimolar concentrations ranging fi’om 10
-4 to 10
-8 M.
Drugs
Commercially available solution for i.v. administration of cisplatin, and taxo! (Ebewe, Austria), served as
stock solution. The range of drugs concentrations, 104-10-9 M, were used, in order to define ICso
concentration for particular time point. The substances of adequate concentrations were added in volume of
10 tL/well.
WST1 assay
Cytotoxicity was evaluated by tetrazolium colorimetric WST1 assay (Boehringer Mannheim).
Exponentially growing cells were harvested and plated into 96-well microtitar plates (Costar) at seeding
density of 5 x 103 cells in a volume of 90 lal per well, and preincubated in complete medium at 310 K for 24
hours (h). Tested substances, at twice the required final concentration, in growth medium (10 tl/well) were
added to all wells except control. Microplates were incubated for 2 h. After the exposure period medium was
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changed and cells were left to recover for 24, 48 and 72 h respectively. The wells containing cells without
tested substances served as control. Two hours before the end of incubation 10 lal of WST1 solution was
added to all wells. Optical density was measured on a spectrophotometer plate reader (Multiscan MCC340,
Labsystems) at 492/690 rim. The wells without cells containing complete medium and WST1 only acted as
blanks. Inhibition of growth was expressed as a percent of control and cytotoxicity was calculated according
to the formula: (1-OD/ODco,t,.o) x 100. The substance potency was expressed as the ICs0 (50% inhibitory
concentration).
Flow Cytometry
Cell cycle analysis. Cell suspension (lx106/ml) was treated with ml 0.1% TRITON-X-100 for 5 rain at
277 K, followed by 20 ILtl RNA-ase (1 mg/ml) in PBS, stained with propidium iodide (PI) and analyzed by
standard procedure. Flow cytometry was performed on FACS Calibur (Becton Dickinson) flow cytometer.
Measurement of apoptosis. Cell suspension (lxl06/ml) was incubated in the dark, in staining buffer
containing 20 gL of PI and 20 laL of Annexin-V in HEPES buffer (Annexin-V-FLUOS kit, Boehringer).
After the incubation period stained cells were resuspended in HEPES buffer and analyzed by standard
procedure. Flow cytometry was performed on a FACS Calibur (Becton Dickinson) flow cytometer.
Data analysis
The IC50 of platinum(II) complexes and taxol as well as the interaction between them were determined
by median effect analysis/11, 12/. The analysis compares the effects of drug combinations to the effects of
individual drugs across the entire dose-effect range, indicating if the interaction is synergistic, additive or
antagonistic. Data in tables and figures represent the mean ofthe quadruplicate wells.
RESULTS
This study evaluates two cisplatin analogues, cis-[PtCI2(CH3SCH2CH2SCH3)] (Ptl) and cis-
[PtCIE(dmso)2] (Pt2; dmso is dimethylsulfoxide), for their potential to inhibit growth of MCF human
Ptl Pt2
cis-[PtCIz(CHsSCH2CH2SCHa)] cis-[PtCl(dmso)2]
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breast cancer cell line. MCF7 cells were exposed to platinum(II) complexes alone or simultaneously with
taxol for 2 hours.The survival of the cells was evaluated by the end of the treatment or after recovery period
of 24, 48 and 72 hours respectively. The effects of drug combinations at the IC25, IC50 and IC75 level were
determined by median effect analysis. The ability to induce apoptosis and cell cycle changes were analyzed
as well.
MCF7 cells were found to be sensitive to both Ptl and Pt2 complexes (Figure 2). The cytotoxicity
profiles of these two platinum(II) complexes are different but each of them influences the cell growth more
effectively as compared to eisplatin at equimolar concentrations (Figure 3). Survival rate depends on
concentration and recovery time.
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Fig. 2: Cytotoxic effect of platinum(ll) complexes: on MCF7 human breast cancer cell line. Cells (5x103)
were exposed to complexes for 2 h, 24 h after plating. Medium was changed and cells were left to
recover for 24, 48 and 72 h respectively. Cytotoxicity was evaluated by tetrazolium WST1 assay at
indicated time points. Bars represents mean of quadriplicate wells.
A profound growth inhibitory effect was observed for Ptl complex, across all its concentrations at each
recovery period. Prolonging the recovery time from 24-72 h increased cytotoxicity of Ptl, reaching plateau
72 h post treatment, at concentrations <1 tM. However, Pt2 decreased MCF7 cells survival only for the first
24 h, ranging between 50-55%. The cytotoxicity sharply decreased thereafter, approaching 2 h treatment
cytotoxicity level. Increasing the concentration above 0.1 M resulted in no additional cytotoxicity
resembling Ptl cytotoxicity pattern. The IC50 values for Ptl and Pt2 are similar, but only for the first 24 h
(0.337 and 0.3051 IM, respectively). The IC50 values for Ptl decreased with recovery period by the factor
10.
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Fig. 3: Comparison of growth inhibitory effect of Ptl and Pt2 complex to cisplatin at 24 h and 72 h post
treatment respectively. Maximal growth inhibitory activity of platinum(II) complexes is shown.
The increased survival ofMCF7 cells was noticed for both complexes above particular concentrations (>
laM for Ptl and >0.1 tM respectively). In order to check out whether the number of surviving cells was
really increased or there was only change in the cell metabolic activity, DET assay was performed under the
same experimental conditions. The results obtained highly corresponded to those of tetrazolium assay. The
linear correlation coefficients were rptl 0.9361 and rpt2 0.9086 respectively (data not shown).
Combinations of platinum(II) complexes and taxol were analyzed by median effect method, primarily
under the assumption that drug mechanisms of action were mutually, nonexclusive i.e. were completely
independent. A drug combination index (CI) was calculated for three different levels of cytotoxicity (25; 50
and 75%). On simultaneous exposure of cells to taxol and platinum(II) complexes no consistent effect was
found. The CIs for drug combinations revealed cytotoxic effects that were in most cases synergistic (Pt l) and
less than additive (Pt2). Median effect analysis showed that interaction of platinum(If) complexes and taxol
varies, depending not only on the type of complex, but also on the cytotoxicity level (Figures 4 and 5).
It is well known that cisplatin can induce apoptosis in various cells, in any cell cycle phase, as a function
of drug concentration and exposure duration, but a period of cell cycle "stasis" precedes the onset of
apoptosis [5, 13, 14]. We examined whether platinum(If) complexes can induce apoptotic cell death in MCF7
cells. Flow cytometry analysis has shown that each platinum(II) complex induced apoptosis in MCF7 cells.
Prolonging the exposure time of cells to platinum(II) complexes, at IC50 concentration, from 2 to 24 h,
increased the total number of apoptotic cells. Both Ptl and Pt2 induce higher apoptosis level at lower
concentrations during the first 24 h post treatment that correlates with cytotoxicity profile of the complexes
(data not shown).
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Fig. 4: Effects of platinum(II) complexes alone and in combination with taxol on MCF7 cell line survival,
determined 48 h post treatment. 24 h after plating cells (5x103) were exposed to complexes for 2 h.
Medium was changed and cells were left to recover. Survival was evaluated by tetrazolium WST1
assay at indicated time points. Bars represents mean of quadruplicate wells.
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Fig. 5:IC50 and combination index(CI) values determined by Median Effect analysis
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Taxol alone induced strong apoptotic response (38.22%), while in combination with Pt2 under the same
experimental conditions, total number of apoptotic cells decreased (30.25%). Pt induced higher total number
of apoptotic cells than Pt2, (24.15 and 13.88 respectively ) at 24 h post treatment but in all other time points
the values were similar (Table 1).
Although cisplatin is cycle-phase nonspecific, cells treated with cytotoxic cisplatin concentrations may
remain arrested at one or more steps of the cell cycle for up to several days prior to cell death/15/. Both
platinum(II) complexes also induced cell cycle perturbations. Cells treated at IC50 concentrations of Ptl and
Pt2 accumulated in G0G phase of cell cycle. Ptl transiently (24 h) increased the number of cells in S phase
of cell cycle. Pt2-treated cells remained arrested in G0G up to 72 h post exposure. Taxol inhibits cell cycle
traverse at the G2M phase junction/16/. It was found that Pt2 in combination with taxol caused further arrest
of cells in G0G phase (24 h) in parallelwith strong decrease of cells in G2M phase cells (Table 2).
Table 1.
Time-related effect ofplatinum(II) complexes on induction of apoptosis in MCF7 cells.
APOPTOSIS (%):
total (early+late)
Drus 2h 4h 24h 2h+24h ’2h+48 2h+72
19.37 18.71 26.9 19.09 27.96 21.5
0 i(5.73+13.64) (5.48+12.87) (5.79+21.11) (7.41+11.68) (0.63+27.33) (3.76+17.74)
23.44 20.08 20.77 20.99
cis-Pt (12.6+10.84) ND ND (5.68+14.4) (1.13+19.63) (3.25+17.74)
24.79 23.35 31.33 24.15 23.54 22.09
Ptl (4.38+20.41) (8.79+14.56) (7.11+24.22) (9.57+14.58) (0.64+22.9) (4.89+17.2)
23.88 26.16 33.99 13.88 22.25 22.28
at2 (10.36+13.25) (3.7+22.46) (6.41+27.58) (2.85+11.03) (1.13+21.12) (3.25+19.03)
38.22 39.68
Taxol ND ND ND (5.12+33.1) (6.98+32.7) ND
30.25
Pt2+T NF" ND ND (3.24+27.01) ND ND
Platinum(II) complexes were applied at IC50 concentrations. The apoptosis was analyzed by Annexin-V
FLUOS assay. Data are given as a percent of apoptotic cell number.
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Ptl
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Pt2+T
Table 2.
Effects of platinum(II) complexes on DNA content ofMCF7 cells.
CELL CYCLE PHASES
GOGI
2h+24
2h h ,2h+48 2h+72
79.49 77.73 73.61 93.67
79.80 79.14 77.55 94.39
79.05 68.79 82.62 92.66
76.61 80.54 99.31 91.39
ND 72.55 ND ND
:S
,2h
3.73
0.97
0.5
12.23
ND
2h+24
h 2h+48 2h+72
8.34 25.8 0.16
9.90 21.84 0.89
0.14 17.38 3.86
49 0.68 0
23.87 ND ND
G2M
2h+24
2h h
16.78 13.93
,19.22 10.96
20.45 31.07
,11.16 14.05
IND 3.58
2h+48 2h+72
0.59 6.17
0.61 4.72
0 3.48
0.01 8.61
ND ND
Platinum(lI) complexes were applied at IC50 concentrations. The DNA content was analyzed by propidium
iodide. Data are given as a percent of cell number at particular cell cycle phase.
DISCUSSION
In this paper we report on in vitro results of antitumor activity, of some non-classical platinum(II)
complexes against human breast cancer cell line. This study showed that two platinum(ll) complexes, Ptl
and Pt2, with sulfur-containing carrier ligands, strongly inhibited growth of MCF7 cells in a dose and time-
dependent manner. They also induced apoptosis and cell cycle changes in treated cells. The interaction of
platinum(ll) complexes and taxol varied depending on the type ofcomplex and the cytotoxicity level.
The tested platinum(ll) complexes are cisplatin analogues. It is recognized that manipulation of the
structure of the leaving groups appears to influence tissue and intracellular distribution of the complexes, but
upon interacting with DNA, the stable, carrier groups presumably determine the structure of the adduct. The
ultimate aim of the modifications of the parent drug is to make analogues that produce a different spectrum of
DNA lesions and so circumvent the problem of resistance to cisplatin/1/. It seems that differences related to
carrier ligands influence both types and frequencies of DNA lesions formed, and consequently, various
growths inhibiting activity could be expected.
Cis-configuration of the tested platinum(ll) complexes was identified as potentially critical for
antineoplastic activity. They are platinum(ll) structures assuming planar shape. Both of them have chlorine
atoms for so-called leaving groups. The "carrier" ligands are cyclic moieties in Ptl, but not in Pt2 complex. It
is already known that structural difference of the carrier ligand may greatly alter the spectrum of antitumor
activity of platinum(ll) complexes. The carrier ligand of Ptl comp,lex consists of two thioether (-SCH3)
groups and its chelation to the Pt center forms a very stable five-member ring. This ring contributes to higher
stability of Ptl than the corresponding Pt2 complex. Difference in the stability between these two complexes
can also be correlated with difference in their toxicity. The carrier ligand of Pt2 complex consists of two
molecules of dimethylsulfoxide. The lower toxicity of Pt2 might be attributed to its faster detoxification. As
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data on pharmaeokinetics and pharmacodinamics of the Ptl and Pt2 complexes have not been available so
far, we can only speculate on their structure-related activity assuming that, as cisplatin analogues, cytotoxic
mechanism(s) similar to that ofthe parent drug could be expected.
The differences among the complexes were also found when the effects of combination with taxol were
studied. Various kinetic of apoptosis-induction and cell cycle changes, induced by individual platinum(II)
complex, can explain, in part, resulting differences of drug combinations. Platinum(II) complexes, especially
Pt2, induce apoptosis earlier and arrest cells in G0G phase of cell cycle. Taxol inhibits cell cycle traverse at
the G2M phase junction/16/. By arresting cells in G0G phase of cell cycle Pt2 inhibited both taxol-induced
mitotic arrest and apoptotic death. So, less than additive cytotoxic effect of Pt2 and taxol combination
corresponds to early and strong arrest of cells in G0G phase by Pt2.
We want to point out that the interaction of taxol and Pt-complexes was evaluated only on simultaneous
exposure of MCF7 cells to the drugs. It is known that interaction of taxol and cisplatin is highly schedule-
and cell-dependent/17,18/. Kano et al. found that on sequential exposure to paclitaxel first, followed by
eisplatin, additive effects were observed in different cell lines including MCF7 cells/17/. On simultaneous
exposure to the drugs additive and subadditive effects were obtained in A549, MCF7 and PAl cells. Our
results with Ptl and Pt2 complexes at least in part correspond with their results. Different mechanisms by
which eisplatin may exert dominance over taxol, suggested in some studies/5/, must be kept in mind as well
as when analysis of Pt2 and taxol interaction is concerned.
CONCLUSION
This study showed that two Ptl and Pt2 complexes containing thio ligands influence the MCF7 cells
growth more effectively as compared to the parent drug. However, they differ in their cytotoxicity profiles
and in their interaction with taxol as well. The cell cycle changes and induction of apoptosis in MCF7 cells
implicate a programmed cell death pathway in cell-killing.
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